Header Logo

Connection

Adam Duerfeldt to Drug Design

This is a "connection" page, showing publications Adam Duerfeldt has written about Drug Design.
Connection Strength

1.150
  1. Total syntheses of (-)-pyrimidoblamic acid and P-3A. J Am Chem Soc. 2014 Feb 05; 136(5):2119-25.
    View in: PubMed
    Score: 0.422
  2. Development of a Grp94 inhibitor. J Am Chem Soc. 2012 Jun 13; 134(23):9796-804.
    View in: PubMed
    Score: 0.377
  3. Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARa Agonists as Leads for Retinal Disorders. J Med Chem. 2020 03 26; 63(6):2854-2876.
    View in: PubMed
    Score: 0.161
  4. Design, synthesis, and biological activity of bicyclic radester analogues as Hsp90 inhibitors. Bioorg Med Chem Lett. 2009 Dec 15; 19(24):6845-50.
    View in: PubMed
    Score: 0.079
  5. Design, synthesis, and biological evaluation of conformationally constrained cis-amide Hsp90 inhibitors. Org Lett. 2009 Jun 04; 11(11):2353-6.
    View in: PubMed
    Score: 0.077
  6. Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding. J Med Chem. 2018 04 12; 61(7):2793-2805.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.